All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...
(AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year ...
CHICAGO - Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group with a market capitalization of $14.71 million, ...
When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...
A joint research team from the LKS Faculty of Medicine (HKUMed) and the Faculty of Science at the University of Hong Kong has uncovered an unexpected interaction between chemotherapeutic agents and a ...
Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...
HYDRINITY Accelerated Skin Science, the fastest growing professional medical skincare brand in the US, is proud to announce their new partnership with Unique Skin, a leading name in advanced ...
The American Association for Cancer Research Annual Meeting 2025 will be held from April 25-30 in Chicago, Illinois, providing a ...
Blue Trust Inc. grew its position in Incyte Co. (NASDAQ:INCY – Free Report) by 124.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 593 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback